Sources & Key Research — 5-MeO-DMT-Assisted Therapy

[1] Ermakova, A. O. et al. (2021). A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology. Read the study.

[2] Reckweg, J. T. et al. (2022). The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). Journal of Neurochemistry. Read the study.

[3] Lerer, L. et al. (2023). Cell-based synthesis of 5-methoxy-N,N-dimethyltryptamine. Psychedelic Medicine. Read the study.

[4] Rucker, J. J. et al. (2024). Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. Journal of Psychopharmacology. Read the study.

[5] CNBC (16 July 2026). Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction. Read more.

[6] atai Life Sciences and Beckley Psytech (October 2025). U.S. FDA Breakthrough Therapy Designation granted to BPL-003 in treatment-resistant depression. Read more.

[7] Roberts, C. et al. (2026). A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression. Journal of Psychopharmacology. Read the study.

[8] atai Life Sciences and Beckley Psytech (1 July 2025). Positive topline results from the Phase 2b study of BPL-003 in patients with treatment-resistant depression. Read more.

[9] Uthaug, M. V. et al. (2019). A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology. Read the study.

[10] Davis, A. K. et al. (2018). The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology. Read the study.

[11] Marsden, J. et al. (2025). 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: an open-label, phase 2, proof-of-concept, clinical trial. Addiction. Read the study.

[12] Uthaug, M. V. et al. (2019). Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology. Read the study.

[13] Jefferson, S. J. et al. (2023). 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology. Read the study.

[14] Reckweg, J. T. et al. (2023). A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Frontiers in Psychiatry. Read the study.

[15] Collyer, C. et al. (2026). Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry. Read the review.

[16] Therapeutic Goods Administration (2023). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Read more.

[17] Lancelotta, R. (2022). 5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous. Human Psychopharmacology. Read the study.

[18] Ortiz Bernal, A. M. et al. (2022). Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: an initial exploratory analysis of the phenomenon's predictors and its emotional valence. Frontiers in Psychiatry. Read the study.

[19] Ortiz Bernal, A. M. et al. (2025). Reactivations associated with the use of 5-MeO-DMT among Spanish-speaking individuals: prevalence, predictors, and emotional valence. Journal of Psychoactive Drugs. Read the study.